Halladay Benjamin 4
4 · Esperion Therapeutics, Inc. · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
Esperion (ESPR) CFO Benjamin Halladay Sells 10,773 Shares
What Happened
- Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics (ESPR), reported a sale of 10,773 shares on 2026-06-17. The shares were disposed at $3.15 each for a total value of $33,989. The transaction is reported as an open-market or private sale (code S).
Key Details
- Transaction date: 2026-06-17; Price: $3.15 per share; Total proceeds: $33,989.
- Shares owned after the transaction: not disclosed in the provided filing summary.
- Footnote: F1 — shares were sold to satisfy tax obligations on vested restricted stock units (RSUs).
- Filing date/accession: reported on Form 4 filed 2026-06-18; appears to be timely (filed the next day).
Context
- This sale was to cover tax withholding on vested RSUs, a common administrative reason for insider sales and not necessarily a signal of management’s view on the company’s prospects. Sales to satisfy taxes are routine and differ from discretionary, investment-motivated purchases.
Insider Transaction Report
Form 4
Halladay Benjamin
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1]2026-06-17$3.15/sh−10,773$33,989→ 702,829 total
Footnotes (1)
- [F1]Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Signature
/s/ Sheldon L. Koenig, by power of attorney|2026-06-18